# China NMPA Drug Inspection - Anhui Jishun Traditional Chinese Medicine Pieces Co., Ltd. - Coptis chinensis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-jishun-traditional-chinese-medicine-pieces-co-ltd/c30e92fa-b52f-4eb3-b9dd-17a2b8731313/
Source feed: China

> China NMPA drug inspection for Anhui Jishun Traditional Chinese Medicine Pieces Co., Ltd. published December 28, 2021. Drug: Coptis chinensis. On December 28, 2021, the Shanghai Municipal Drug Administration published Announcement No. 37, detailing the results of

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shanghai Municipal Drug Administration's Announcement on the Fourth Round of Drug Quality Sampling Inspections in 2021 (December 28, 2021)
- Company Name: Anhui Jishun Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2021-12-28
- Drug Name: Coptis chinensis
- Inspection Finding: Non-compliance with regulations, involving the following items: properties and processing methods.
- Action Taken: Enterprises are required to take risk control measures such as ceasing sales, ceasing use, and recalling products, and will be investigated and punished in accordance with the law.
- Summary: On December 28, 2021, the Shanghai Municipal Drug Administration published Announcement No. 37, detailing the results of the fourth batch of drug quality sampling inspections for 2021. The inspections identified quality failures across several pharmaceutical manufacturers, including Anhui Jishun Traditional Chinese Medicine Slices Co., Ltd., Shanghai Zhengda General Pharmaceutical Co., Ltd., Yunnan Jinke Pharmaceutical Co., Ltd., and Jiangxi Pinxin Pharmaceutical Co., Ltd. The main violations involved ten batches of products and included discrepancies in physical appearance, improper processing of herbal medicines, excessive moisture levels, and failures in content determination. Additionally, significant issues regarding microbial limits were discovered in creams and granules, while weight and content variation failures were found in tablet and granule formulations. These inspections were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 and 2020 Editions), focusing on the safety, efficacy, and purity of marketed drugs. In response to these findings, the Shanghai Municipal Drug Administration has mandated immediate actions, including the suspension of sales and use, as well as the recall of all non-compliant products. Regulatory departments are currently conducting legal investigations into the involved enterprises to ensure public safety and maintain market order.

Company: https://www.globalkeysolutions.net/companies/anhui-jishun-traditional-chinese-medicine-pieces-co-ltd/bbaa4df4-c09e-479d-97b0-49152f20c69b/